EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 40 / No 11 (Novembre 2024) Med Sci (Paris), 40 11 (2024) 848-857 References
Open Access
Issue
Med Sci (Paris)
Volume 40, Number 11, Novembre 2024
Page(s) 848 - 857
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2024151
Published online 10 December 2024
  1. Singh V, Khan N, Jayandharan GR. Vector engineering, strategies and targets in cancer gene therapy. Cancer Gene Ther 2022 ; 29 : 402–17. [CrossRef] [PubMed] [Google Scholar]
  2. Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med 2018 ; 10 : eaao5931. [CrossRef] [PubMed] [Google Scholar]
  3. June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science 2018 ; 359 : 1361–5. [CrossRef] [PubMed] [Google Scholar]
  4. Paulson KG, Voillet V, McAfee MS, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 2018 ; 9 : 3868. [Google Scholar]
  5. Rosenberg SA, Eberlein TJ, Grimm EA, et al. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery 1982 ; 92 : 328–36. [PubMed] [Google Scholar]
  6. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986 ; 233 : 1318–21. [CrossRef] [PubMed] [Google Scholar]
  7. Sadelain M. Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. Methods Mol. Med. 1997 ; 7 : 241–8. [Google Scholar]
  8. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989 ; 86 : 10024–8. [CrossRef] [PubMed] [Google Scholar]
  9. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993 ; 90 : 720–4. [CrossRef] [PubMed] [Google Scholar]
  10. Sadelain M. CD19 CAR T Cells. Cell 2017 ; 171 : 1471. [CrossRef] [PubMed] [Google Scholar]
  11. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007 ; 15 : 825–33. [Google Scholar]
  12. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006 ; 12 : 6106–15. [CrossRef] [PubMed] [Google Scholar]
  13. Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021 ; 12 : 81. [CrossRef] [Google Scholar]
  14. Stegen SJC van der, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015 ; 14 : 499–509. [CrossRef] [PubMed] [Google Scholar]
  15. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012 ; 119 : 3940–50. [CrossRef] [PubMed] [Google Scholar]
  16. Ramos CA, Rouce R, Robertson CS, et al. In Vivo Fate and Activity of Second-versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas. Mol Ther 2018 ; 26 : 2727–37. [Google Scholar]
  17. Schubert M-L, Schmitt A, Hückelhoven-Krauss A, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol 2023 ; 16 : 79. [CrossRef] [PubMed] [Google Scholar]
  18. Enblad G, Karlsson H, Gammelgård G, et al. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res 2018 ; 24 : 6185–94. [CrossRef] [PubMed] [Google Scholar]
  19. Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol 2022 ; 13 : 1034707. [CrossRef] [PubMed] [Google Scholar]
  20. Glienke W, Dragon AC, Zimmermann K, et al. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Front Immunol 2022 ; 13 : 839783. [CrossRef] [PubMed] [Google Scholar]
  21. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 2015 ; 15 : 1145–54. [CrossRef] [PubMed] [Google Scholar]
  22. Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019 ; 120 : 26–37. [CrossRef] [PubMed] [Google Scholar]
  23. Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, et al. CAR-T Cell Therapy: From the Shop to Cancer Therapy. Int J Mol Sci 2023 ; 24 : 15688. [CrossRef] [PubMed] [Google Scholar]
  24. Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol 2023 ; 16 : 97. [CrossRef] [PubMed] [Google Scholar]
  25. Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 2018 ; 11 : 132. [CrossRef] [PubMed] [Google Scholar]
  26. Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells 2024 ; 13 : 146. [CrossRef] [PubMed] [Google Scholar]
  27. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017 ; 543 : 113–7. [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
  28. Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: Elements and their synergistic function. EBioMedicine 2020 ; 58 : 102931. [CrossRef] [PubMed] [Google Scholar]
  29. Lamers CHJ, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006 ; 24 : e20–2. [CrossRef] [PubMed] [Google Scholar]
  30. Lamers CH, Sleijfer S, Steenbergen S van, et al. Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity. Mol Ther 2013 ; 21 : 904. [Google Scholar]
  31. Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023 ; 14 : 1113882. [CrossRef] [Google Scholar]
  32. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022 ; 28 : 2124–32. [Google Scholar]
  33. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med 2024 ; 390 : 687–700. [CrossRef] [PubMed] [Google Scholar]
  34. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016 ; 127 : 3321–30. [CrossRef] [PubMed] [Google Scholar]
  35. Kadauke S, Myers RM, Li Y, et al. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol 2021 ; 39 : 920–30. [CrossRef] [PubMed] [Google Scholar]
  36. Gust J, Hay KA, Hanafi L-A, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 2017 ; 7 : 1404–19. [CrossRef] [PubMed] [Google Scholar]
  37. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 2016 ; 9 : 70. [CrossRef] [PubMed] [Google Scholar]
  38. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther J 2010 ; 18 : 843–51. [CrossRef] [Google Scholar]
  39. Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 2018 ; 24 : 1504–6. [CrossRef] [PubMed] [Google Scholar]
  40. Kankeu Fonkoua LA, Sirpilla O, Sakemura R, et al. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther - Oncolytics 2022 ; 25 : 69–77. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.